Effects of ezetimibe on postprandial hyperlipidaemia and hyperglycemia in Japanese hyperlipidemic patients; Double-blinded crossover randomized clinical trial

Effects of ezetimibe on postprandial hyperlipidaemia and hyperglycemia in Japanese hyperlipidemic patients; Double-blinded crossover randomized clinical trial - Effects of ezetimibe on postprandial hyperlipidaemia and hyperglycemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002954

Enrollment

120

Registered

2010-01-05

Start date

2009-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperlipidemic subjects

Interventions

Subjects will be assigned randomly to ezetimibe precedence treated group and placebo precedence treated group.Subjects in ezetimibe precedence treated group will be received ezetimibe 10 mg/day for th

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1.waist 85cm or more, BMI 25kg/m2 or more 2.TG:150~400 mg/dL

Exclusion criteria

Exclusion criteria: 1.Subjects who are hypersensitive to this medicine and/or contaminants of this medicine. 2.Subjects who have a severe hepatic or renal dysfunction. 3.Subjects who have already been treated with anti-dyslipidemic and/or anti-diabetic agent within 3 months of the study entry

Design outcomes

Primary

Measure	Time frame
1.The change in serum lipid levels(TG,Apo48,RLP-C, oxidized cholesterol)	—

Secondary

Measure	Time frame
1.The alteration in glucose metabolism 2.The change in serum hs-CRP, TNF- 3.The change in serum total adiponectin concentration	—

Countries

Japan

Contacts

Public ContactKaori Kikuchi

Graduate School of Medicine, Yokohama City University Department of Endocrinology and Metabolism

t086028f@yokohama-cu.ac.jp+45-787-2639

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026